🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

LXRX LXRX

Company Profile ↓
$2.45
+118.75% 1Y
Mkt Cap$896.33M
P/E-17.50
P/B8.34
52W High$2.64
52W Low$1.04
Book Value$0.29
EPS (TTM)$-0.14

Company Overview

LXRX (LXRX) is a publicly traded company listed on with a market capitalization of $896.33M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 10.8% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $49.80M (+60.2% YoY); net profit $-50.34M.
  • Trailing 12 Months Year-on-year growth — revenue +60.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.80%
1 Year:60.24%

Stock Price Performance

1 Year:+118.75%
6 Months:+91.41%
3 Months:+48.48%
1 Month:+3.38%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
$1.04 $2.64
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)59.61 · Neutral
Price Performance
1M+3.38%
3M+48.48%
6M+91.41%
1Y+118.75%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.8% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-17.50
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$0.29
Price to Book
8.34
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
10.80%
Profit 5Y
-
Revenue (YoY)
60.24%
Earnings (YoY)
-

Profitability & Returns

ROCE
-29.80%
ROE
-46.81%
ROA
-27.21%
Profit Margin
-
Op Margin
-98.21%
Gross Margin
99.45%
EPS (Latest Qtr)
$0.00
EPS (TTM)
$-0.14

Balance Sheet & Liquidity

Debt/Equity
0.58
Quick Ratio
4.87
Current Ratio
4.88
Debt
$62.82M
Total Assets
$268.82M
Current Assets
$101.89M
Working Capital
$81.03M

Ownership

Promoter Holding
1.12%
Chg in Prom Hold
-
FII / Inst Holding
78.59%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$49.80M
EBITDA
$-41.38M
Free Cash Flow
$-67.85M
Operating Cash Flow
$-67.85M
Shares Outstanding
365.85M
Gross Margin
99.45%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------19.83M6.40M556.00K-2.44M860.00K285.91M-8.00K25.00K0000-000291.00K148.00K1.09M1.62M1.74M1.26M---
Operating Income -3.45M-26.53M-26.69M-33.68M88.36M-33.87M-37.02M-34.93M-31.33M-39.51M-33.49M-28.61M-29.02M-37.71M-30.27M-22.93M-12.37M-17.47M-18.55M224.68M-47.22M-62.44M-64.58M86.67M-20.84M-17.96M-22.96M-23.38M-24.01M-23.09M-31.14M-44.24M-49.63M-45.33M-55.35M-63.69M-25.68M3.74M-12.19M-996.00K
Net Income -2.93M-28.08M-28.07M-35.28M--34.88M-38.11M-36.02M-32.42M-31.92M-34.66M-29.81M-26.61M-41.82M-34.55M-27.40M-16.78M-21.80M-23.02M226.09M-51.14M-66.61M-69.07M82.60M-20.96M-18.07M-23.12M-23.48M-24.59M-23.39M-31.93M-44.90M-50.52M-48.40M-53.43M-64.81M-25.30M3.25M-12.77M-1.04M
Diluted EPS --0.27-0.27-0.340.76-----------0.26--0.21-0.221.95-0.48--0.71---0.16---0.13-0.17-0.22-0.21-0.20-0.17-0.18-0.070.01-0.040.00
R&D Expense -20.86M20.77M23.11M-37.00M48.22M52.53M-43.58M26.93M39.14M-47.70M26.48M13.76M-12.02M12.64M26.66M-55.18M57.30M40.15M12.61M10.26M15.68M14.93M13.36M10.56M12.03M14.54M17.56M14.37M17.64M25.78M15.30M15.75M18.76M12.76M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 10.70M4.91M1.85M1.09M2.22M22.85M130.01M015.89M26.58M32.33M23.40M-139.00K1.20M31.08M49.80M
Cost of Revenue -------------085.00K616.00K274.00K
Gross Profit -------------139.00K1.12M30.46M49.53M
Operating Expenses -------------100.90M172.87M227.58M98.44M
Operating Income -89.96M-95.72M-114.09M-108.42M-102.37M-100.37M1.47M-127.17M-130.62M-103.28M141.44M-47.80M--100.76M-171.75M-197.12M-48.91M
EBITDA --------------98.74M-163.46M-184.29M-41.38M
Interest Expense -------------2.78M13.10M15.58M8.34M
Pretax Income --------------101.94M-177.12M-200.40M-50.34M
Tax Provision ------------0----
Net Income -82.78M-101.78M-116.22M-110.21M-104.13M-100.29M-4.68M-131.44M-122.99M-120.55M130.13M-58.57M--101.94M-177.12M-200.40M-50.34M
Diluted EPS ---------1.17-1.141.16-0.53--0.62-0.79-0.63-0.14
R&D Expense 81.24M78.52M91.83M82.57M89.68M89.28M95.19M163.97M152.22M100.24M91.92M153.62M55.05M52.82M58.89M84.48M61.12M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --366.88M430.51M371.78M274.16M471.38M651.96M475.62M436.54M284.14M417.71M203.79M-194.30M229.43M298.42M184.99M
Current Assets --------------140.87M176.55M246.19M101.89M
Cash & Equivalents 85.87M100.55M47.21M186.31M30.42M37.50M137.27M202.99M46.60M61.66M80.39M36.11M126.26M-46.34M22.46M66.66M34.33M
Inventory --------------0381.00K231.00K281.00K
Receivables --------------28.00K1.01M3.47M2.38M
Total Liabilities --119.86M132.94M105.10M104.00M187.36M366.11M318.22M368.27M310.54M300.61M47.42M-77.17M136.32M152.47M77.45M
Current Liabilities --10.78M21.39M18.29M19.29M44.97M122.96M164.64M105.49M36.75M65.34M46.81M-23.17M31.55M45.25M20.87M
Long Term Debt --27.34M23.45M21.88M20.17M87.50M100.96M85.17M231.58M243.89M234.17M0-48.58M99.51M100.30M49.41M
Total Debt --------------55.29M106.06M108.40M62.82M
Total Equity 195.83M163.50M247.02M297.57M266.68M170.16M284.02M285.97M167.51M68.27M-26.41M117.10M156.37M-117.12M93.11M145.95M107.54M
Shares Outstanding --------------189.21M245.79M363.02M365.85M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -89.02M-82.37M-87.94M-94.46M-91.08M-75.62M184.78M-175.63M-185.39M-148.61M113.81M-142.97M-87.02M-88.85M-161.90M-178.78M-67.85M
Investing Cash Flow 11.88M-113.84M69.95M-97.81M99.54M-108.42M-117.02M18.25M50.52M169.58M-155.85M380.76M2.11M-71.08M-49.94M-15.38M113.02M
Financing Cash Flow 91.82M142.87M157.08M36.38M-1.39M283.81M-2.03M987.00K149.93M-2.24M-2.23M-147.64M22.71M142.21M187.96M238.35M-48.50M
Capital Expenditure -369.00K-1.13M-1.21M-492.00K-1.72M-80.00K-910.00K-231.00K-228.00K-95.00K-70.00K-87.00K-1.22M-1.33M-470.00K-1.03M-0
Free Cash Flow -89.39M-83.50M-89.14M-94.95M-92.80M-75.70M183.87M-175.86M-185.62M-148.70M113.74M-143.06M-88.24M-90.18M-162.37M-179.81M-67.85M
Share Buybacks 88.00K149.00K108.00K285.00K873.00K887.00K357.00K621.00K1.68M972.00K941.00K1.03M2.67M864.00K824.00K1.73M-

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------100.0%92.9%98.0%99.4%
Operating Margin % -840.7%-1,950.2%-6,170.6%-9,955.5%-4,607.2%-439.2%1.1%--822.1%-388.5%437.5%-204.2%--72,489.2%-14,265.0%-634.2%-98.2%
Net Margin % -773.6%-2,073.7%-6,285.3%-10,120.4%-4,686.1%-438.8%-3.6%--774.0%-453.5%402.5%-250.3%--73,341.0%-14,710.9%-644.8%-101.1%
ROE % -50.6%-41.2%-39.1%-41.3%-61.2%-35.3%-1.6%-78.5%-180.2%456.5%111.1%-37.5%--87.0%-190.2%-137.3%-46.8%
ROCE % --26.9%-27.9%-30.7%-40.2%-23.5%0.3%-40.9%-39.5%-41.7%40.1%-30.4%--58.9%-86.8%-77.9%-29.8%

Shareholding Pattern

Insiders
1.12%
Institutions
78.59%
Public Float
79.49%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LXRX

Google News hu, 11 Jun 2026

Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQRlBLNVlPOWk3bEstSU5CMFRMUGtiYU9NUkluMThVZHNJUUF4dnRIZnNZckczenpVTnhMdVFXbFJURE0zVExpZm5zTnl4WEpyWUh1WVREVUxDekdRZ2UtenFiY2tSSC1DUGozRTVqVnU5Ry1lS3pabHBJbFMxdWhON09RYUdsNHJHTDdpa3…

Google News ue, 04 Aug 2026

Why Lexicon Pharmaceuticals (LXRX) Is Up 6.4% After Completing Randomization in Pivotal SONATA-HCM Trial - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxQOXpQTUdXVUJ5MUZtczBSUzdYcDRzUE9qakxqZi1EblJ3WWxKczRUenV6MndBaW43TWdia3VKTVFYZHptUTFUUmpVUTR1eXJILU5oQkRWY2hvX2ZaNmNaS1dHSW9WM2VTankxMXBQLUJmYllyaHRVcndXaExOUmRVMUU4d0hDcm5OREhPZ3…

Google News hu, 30 Jul 2026

Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOS25lSzBoY2hYTkJIN2FxeEFDLWhYdTlVTEoxX1FfUXp1eE5aWnVKYUgtX3pNTkRtdXhERDkzNnBUcTI1ZEU1Q29sQ2M5ZEFQMXFyNEF0d2xwSkRtR2wyX2tjT1BMZ2VjdXFOeTNzcEV1bmdTanNqa3p5TzF1VGR5YjFCTUlGbjVRWVA5Zk…

Google News ue, 30 Jun 2026

$LXRX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQS002QkN5ZmlDVWxlbTk0T2FzbUxOeGZMN3lRR1NIUkx4cV9ONy10bG9PbmZrd0RXdlRra0FrVmVxVXI5alFrZTNqQzQ0YkpkZmJKeVlnNEdPRG03RzYxLTlKOXl6M2R0N2ZfX0tESHR0ajNpT2tVRXFOSnljMGh4SWF4Q2NyM0lUVm9PZ2…

Google News Sun, 26 Jul 2026

Price to sales forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxORm1BSVFhZllXcXRUZVFKTFJkQ3hoR0R4YjhDYnB5anVNbGFZZ2NiWER0N3BsRGZMbzE3YlhXQnFLeWRSa3NZUzVabFVLcWdHMWU4RVlYbnV3RUgwTUVRTmVIWHZsWnVkWVhWRVlZMUd1VjVMMmVqeVhJdllvalVPOHFQaGxlUno1MmxHTm…

Google News Fri, 22 May 2026

Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPX2FTbGpINHRlbE1SUlZDQ1BPa001QUhkT0FmMjNJbzU1aXdveHhrLTZPRHVibHVyTkdQenRTREt2dXFyRVZIVEROX2dfUUE3STJUdXNXWWNWR0VGUERsZno2T3pEMklYOFhmdnR0blZxbjFVa19LZk0xRUJCZ0F3bFdOSzNIMmR3ZHMyMz…

LXRX — Frequently Asked Questions

What is the current share price of LXRX?

As of 2026-08-05 17:25 PDT, LXRX trades at $2.45 on NASDAQ/NYSE. Its 52-week range is $1.04 to $2.64.

What is the market capitalisation of LXRX?

LXRX has a market capitalisation of $896.33M on NASDAQ/NYSE.

What is the P/E ratio of LXRX?

LXRX trades at a trailing price-to-earnings (P/E) ratio of -17.50. Its price-to-book (P/B) ratio is 8.34.

What is the return on equity (ROE) of LXRX?

LXRX has a return on equity (ROE) of -46.81%. Its return on capital employed (ROCE) is -29.80%.

Is LXRX a good stock to buy?

This page provides a data-driven analysis of LXRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space